BioXcel Therapeutics (BTAI) Non Operating Income (2018 - 2022)

BioXcel Therapeutics' Non Operating Income history runs 5 years deep, the most recent figure standing at $62000.0 for Q3 2022.

• On a quarterly basis, Non Operating Income rose 6100.0% year-over-year to $62000.0 in Q3 2022; TTM through Sep 2022 was $164000.0, a 31.67% decrease from a year earlier, with the FY2019 full-year figure at $633000.0, down 8.53% from the prior year.
• Non Operating Income rose to $62000.0 in Q3 2022 per BTAI's latest filing, from $1000.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $238000.0 in Q4 2018 and bottomed at $1000.0 in Q3 2021.
• The 5-year median for Non Operating Income is $127000.0 (2019), against an average of $124083.3.
• Across the five-year window, Non Operating Income sank 90.24% in 2020 and surged 6100.0% in 2022, its largest moves.
• Year by year, Non Operating Income stood at $238000.0 in 2018, then plunged by 42.02% to $138000.0 in 2019, then plunged by 88.41% to $16000.0 in 2020, then tumbled by 93.75% to $1000.0 in 2021, then jumped by 6100.0% to $62000.0 in 2022.
• Per Business Quant, the three latest BTAI Non Operating Income figures stand at $62000.0 (Q3 2022), $1000.0 (Q3 2021), and $16000.0 (Q2 2020).